NasdaqGS:ARVNPharmaceuticals
Arvinas (ARVN): Valuation Discount Persists as Losses Widen, Challenging Hope for Profit Turnaround
Arvinas (ARVN) continues to operate at a loss, with net losses increasing at an average rate of 7.7% per year over the past five years and no signs of profit growth acceleration. Revenue is forecast to grow slowly at just 1.1% per year, a pace that lags well behind the broader US market’s 10.5% growth rate. Despite these challenges, investors will weigh the potential reward of a low Price-To-Sales Ratio of 1.9x, which is much lower than peers, against the sustained losses and subpar revenue...